<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://toxsci.oxfordjournals.org">
<title>Toxicological Sciences - current issue</title>
<link>http://toxsci.oxfordjournals.org</link>
<description>Toxicological Sciences - RSS feed of current issue</description>
<prism:eIssn>1096-0929</prism:eIssn>
<prism:coverDisplayDate>June 2008</prism:coverDisplayDate>
<prism:publicationName>Toxicological Sciences</prism:publicationName>
<prism:issn>1096-6080</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/225?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/228?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/241?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/260?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/268?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/278?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/285?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/298?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/311?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/325?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/335?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/346?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/354?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/362?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/371?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/382?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/397?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/409?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/411?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/414?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/416?rss=1" />
  <rdf:li rdf:resource="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/417?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/225?rss=1">
<title><![CDATA[Nicotine and Type 2 Diabetes]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/225?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Borowitz, J. L., Isom, G. E.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn050</dc:identifier>
<dc:title><![CDATA[Nicotine and Type 2 Diabetes]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>227</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>225</prism:startingPage>
<prism:section>TOXICOLOGICAL HIGHLIGHT</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/228?rss=1">
<title><![CDATA[miRNAs: Effectors of Environmental Influences on Gene Expression and Disease]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/228?rss=1</link>
<description><![CDATA[
<p>Discovered less than a decade ago, micro-RNAs (miRNAs) have emerged as important regulators of gene expression in mammals. They consist of short nucleic acids, on average ~22 nucleotides in length. The miRNAs exert their effect by binding directly to target messenger RNAs (mRNAs) and inhibiting mRNA stability and translation. Each miRNA can bind to multiple targets and many miRNAs can bind to the same target mRNA, allowing for a complex pattern of regulation of gene expression. Once bound to their targets, miRNAs can suppress translation of the mRNA by either sequestration or degradation of the message. Thus, miRNAs function as powerful and sensitive posttranscriptional regulators of gene expression. This review will summarize what is known about miRNA biogenesis, expression, regulation, function, mode of action, and role in disease processes with an emphasis on miRNAs in mammals. We discuss some of the methodology employed in miRNA research and the potential of miRNAs as therapeutic targets. The role of miRNAs in signal transduction and cellular stress is reviewed. Lastly, we identify new exciting avenues of research on the role of miRNAs in toxicogenomics and the possibility of epigenetic effects on gene expression.</p>
]]></description>
<dc:creator><![CDATA[Hudder, A., Novak, R. F.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn033</dc:identifier>
<dc:title><![CDATA[miRNAs: Effectors of Environmental Influences on Gene Expression and Disease]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>240</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>228</prism:startingPage>
<prism:section>REVIEW</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/241?rss=1">
<title><![CDATA[Tissue Exposures to Free and Glucuronidated Monobutylyphthalate in the Pregnant and Fetal Rat following Exposure to Di-n-butylphthalate: Evaluation with a PBPK Model]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/241?rss=1</link>
<description><![CDATA[
<p>Human exposure to phthalic acid diesters occurs through a variety of pathways as a result of their widespread use in plastics. Repeated doses of di-n-butylphthalate (DBP) from gestation day (GD) 12 to 19 disrupt testosterone synthesis and male sexual development in the fetal rat. To gain a better understanding of the relationship of the target tissue (testes) dose to observed developmental effects, the pharmacokinetics of monobutyl phthalate (MBP) and its glucuronide (MBP-G) were examined in pregnant and fetal rats following single and repeated administration of DBP from GD 12&ndash;19. These data, together with results from previously published studies, were used to develop a physiologically based pharmacokinetic model for DBP and its metabolites in the male, pregnant and fetal rat. The model structure accounts for the major metabolic (hydrolysis, glucuronidation, oxidative metabolism) and transport processes (enterohepatic recirculation, urinary and fecal excretion, placental transfer). Extrapolation of the validated adult male rat model to gestation successfully predicts MBP and MBP-G levels in maternal plasma, placenta and urine, as well as the fetal plasma and testes. Sensitivity analysis indicates that plasma MBP kinetics are particularly sensitive to glucuronidation and enterohepatic recirculation: a decrease in the uridine 5'-diphospho-glucuronosyltransferase (UDPGT) capacity during gestation results in an increased MBP residence time, and saturation of UDPGT at the highest doses (&gt; 100 mg/kg/day) causes a flattening out of the plasma time course data. Oxidative metabolism plays a significant role in elimination only at low doses (&lt; 50 mg/kg DBP). Insights gained from modeling of the rat data will be used to support development of a human PBPK model for DBP.</p>
]]></description>
<dc:creator><![CDATA[Clewell, R. A., Kremer, J. J., Williams, C. C., Campbell, J. L., Andersen, M. E., Borghoff, S. J.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn054</dc:identifier>
<dc:title><![CDATA[Tissue Exposures to Free and Glucuronidated Monobutylyphthalate in the Pregnant and Fetal Rat following Exposure to Di-n-butylphthalate: Evaluation with a PBPK Model]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>259</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>241</prism:startingPage>
<prism:section>BIOTRANSFORMATION AND TOXICOKINETICS</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/260?rss=1">
<title><![CDATA[Tumor Promotion in Liver of Mice with a Conditional Cx26 Knockout]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/260?rss=1</link>
<description><![CDATA[
<p>Connexin (Cx) 26 and 32 are the major gap junction proteins in liver. We recently demonstrated that Cx32 is essential for phenobarbital (PB)&ndash;mediated tumor promotion in mouse liver. To investigate whether Cx26 plays a similar role, an initiation-promotion experiment was conducted using mice with a liver-specific knockout of Cx26. Control and Cx26-deficient mice were injected a single dose of N-nitrosodiethylamine (DEN, 90 &micro;g/g b.wt.) at 6 weeks of age and groups of mice were subsequently kept on a PB (0.05%) containing or control diet for 35 weeks. At the end of the experiment, the carcinogenic response in the liver was monitored. Mice from PB treatment groups showed strongly increased liver weights compared with mice treated with DEN alone, which was mostly due to a much higher tumor burden. The tumor response in PB-treated mice of both strains was quite similar, but the number of smaller tumors and of enzyme-altered neoplastic lesions was somewhat larger in PB-treated Cx26 knockout (Cx26 KO) compared with wild-type mice, whereas the volume fraction of enzyme-altered lesions was slightly reduced in PB-treated Cx26-deficient mice. There was no significant difference in tumor prevalence between Cx26 KO and wild-type mice. Altogether our present data show that elimination of Cx26 has only minor effects on chemically induced mouse hepatocarcinogenesis, in striking contrast to the effects seen in Cx32 KO mice.</p>
]]></description>
<dc:creator><![CDATA[Marx-Stoelting, P., Mahr, J., Knorpp, T., Schreiber, S., Templin, M. F., Ott, T., Buchmann, A., Schwarz, M.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn043</dc:identifier>
<dc:title><![CDATA[Tumor Promotion in Liver of Mice with a Conditional Cx26 Knockout]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>267</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>260</prism:startingPage>
<prism:section>CARCINOGENICITY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/268?rss=1">
<title><![CDATA[Phthalate Induction of CYP3A4 is Dependent on Glucocorticoid Regulation of PXR Expression]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/268?rss=1</link>
<description><![CDATA[
<p>Cytochrome P450 3A4 (CYP3A4) is responsible for oxidative metabolism of more than 60% of all pharmaceuticals. CYP3A4 is inducible by xenobiotics that activate pregnane X receptor (PXR), and enhanced CYP3A4 activity has been implicated in adverse drug interactions. Recent evidence suggest that the widely used plasticizer, di-2-ethylhexyl phthalate (DEHP), and its primary metabolite mono-2-ethylhexyl phthalate (MEHP) may act as agonists for PXR. Hospital patients are uniquely exposed to high levels of DEHP as well as being administered glucocorticoids. Glucocorticoids positively regulate PXR expression in a glucocorticoid receptor (GR)&ndash;mediated mechanism. We suggest that the magnitude of CYP3A4 induction by phthalates is dependent on the expression of PXR and may be significantly higher in the presence of glucocorticoids. DEHP and MEHP induced PXR-mediated transcription of the CYP3A4 promoter in a dose-dependent fashion. Coexposure to phthalates and dexamethasone (Dex) resulted in enhanced CYP3A4 promoter activity; furthermore, this induction was abrogated by both the GR antagonist RU486 and GR small interfering ribonucleic acid. Dex induced PXR protein expression in human hepatocytes and a liver-derived rat cell line. CYP3A4 protein was highly induced by Dex and DEHP coadministration in human hepatocyte cultures. Finally, enhanced 6&beta;-hydroxytestosterone formation in Dex and phthalate cotreated human hepatocytes confirmed CYP3A4 enzyme induction. Concomitant exposure to glucocorticoids and phthalates resulting in enhanced metabolic activity of CYP3A4 may play a role in altered efficacy of pharmaceutical agents. Understanding the role of glucocorticoid regulation of PXR as a key determinant in the magnitude of CYP3A4 induction by xenobiotics may provide insight into adverse drug effects in a sensitive population.</p>
]]></description>
<dc:creator><![CDATA[Cooper, B. W., Cho, T. M., Thompson, P. M., Wallace, A. D.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn047</dc:identifier>
<dc:title><![CDATA[Phthalate Induction of CYP3A4 is Dependent on Glucocorticoid Regulation of PXR Expression]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>277</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>268</prism:startingPage>
<prism:section>ENDOCRINE TOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/278?rss=1">
<title><![CDATA[Clinical Manifestations and Arsenic Methylation after a Rare Subacute Arsenic Poisoning Accident]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/278?rss=1</link>
<description><![CDATA[
<p>One hundred and four workers ingested excessive levels of arsenic in an accident caused by leakage of pipeline in a copper-smelting factory. Clinical examinations were performed by physicians in a local hospital. Excreted urinary arsenic species were determined by cold trap hydride generation atomic absorption spectrometry. In the initial toxic phase, gastrointestinal symptoms were predominant (83 people, 79.8%). Most patients showed leucopenia (72 people, 69.2%), and increased serum alanine aminotransferase (84 people, 80.8%) and aspartate aminotransferase (58 people, 55.8%). Thirty-five patients (33.6%) had elevated red blood cells in urine. After 17 days of admission, many subjects (45 people, 43.3%) developed peripheral neuropathy and 25 of these 45 patients (24.0%) showed a decrease in motor and sensory nerve conduction velocity. In the comparison of urinary arsenic metabolites among subacute arsenic-poisoned, chronic high arsenic&ndash;exposed and control subjects, we found that subacute arsenic-poisoned patients had significantly elevated proportions of urinary inorganic arsenic (iAs) and methylarsonic acid (MMA) but reduced proportion of urinary dimethylarsinic acid (DMA) compared with chronic high arsenic&ndash;exposed and control subjects. Chronic exposed subjects excreted higher proportions of iAs and MMA but lower proportions of DMA in urine compared with control subjects. These results suggest that gastrointestinal symptoms, leucopenia, and hepatic and urinary injury are predominant in the initial phase of subacute arsenic poisoning. Peripheral neuropathy is the most frequent manifestation after the initial phase. The biomethylation of arsenic decreases in a dose rate&ndash;dependent manner.</p>
]]></description>
<dc:creator><![CDATA[Xu, Y., Wang, Y., Zheng, Q., Li, B., Li, X., Jin, Y., Lv, X., Qu, G., Sun, G.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn041</dc:identifier>
<dc:title><![CDATA[Clinical Manifestations and Arsenic Methylation after a Rare Subacute Arsenic Poisoning Accident]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>284</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>278</prism:startingPage>
<prism:section>ENVIRONMENTAL TOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/285?rss=1">
<title><![CDATA[Comparative Temporal Toxicogenomic Analysis of TCDD- and TCDF-Mediated Hepatic Effects in Immature Female C57BL/6 Mice]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/285?rss=1</link>
<description><![CDATA[
<p>Temporal analyses were performed on hepatic tissue from immature female C57BL/6 mice in order to compare the gene expression profiles for 2,3,7,8-tetrachlorodibenzo-<I>p</I>-dioxin (TCDD) and 2,3,7,8-tetrachlorodibzofuran (TCDF). Time course studies conducted with a single oral dose of 300 &micro;g/kg TCDF or 30 &micro;g/kg TCDD were used to compare differential gene expression on complementary DNA microarrays containing 13,361 features, representing 8194 genes at 2, 4, 8, 12, 24, 72, 120, and 168 h. One hundred and ninety-five genes were identified as differentially regulated by TCDF, of which 116 genes were in common with TCDD, with 109 exhibiting comparable expression profiles (correlation coefficients &gt; 0.3). In general, TCDF was less effective in eliciting hepatic vacuolization, and differential gene expression compared with TCDD when given at an equipotent dose based on a toxic equivalence factor (TEF) of 0.1 for TCDF, especially 72-h postadministration. For example, the induction of Cyp1a1 messenger RNA by TCDF was less when compared TCDD. Moreover, TCDF induced less severe hepatocyte cytoplasmic vacuolization consistent with lower lipid accumulations which significantly subsided by 120 and 168 h when compared with TCDD. TCDF-elicited responses correlated with their hepatic tissue levels which gradually decreased between 18 and 168 h. Although both compounds elicited comparable gene expression profiles, especially at early time points, the TCDF responses were generally weaker. Collectively, these results suggest that the weaker TCDF responses could be attributed to differences in pharmacokinetics. However, more comprehensive dose&ndash;response studies are required at optimal times for each end point of interest in order to investigate the effect of pharmacokinetic differences on relative potencies that are important in establishing TEFs.</p>
]]></description>
<dc:creator><![CDATA[N'Jai, A., Boverhof, D. R., Dere, E., Burgoon, L. D., Tan, Y. S., Rowlands, J. C., Budinsky, R. A., Stebbins, K. E., Zacharewski, T. R.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn053</dc:identifier>
<dc:title><![CDATA[Comparative Temporal Toxicogenomic Analysis of TCDD- and TCDF-Mediated Hepatic Effects in Immature Female C57BL/6 Mice]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>297</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>285</prism:startingPage>
<prism:section>ENVIRONMENTAL TOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/298?rss=1">
<title><![CDATA[Liver Genomic Responses to Ciguatoxin: Evidence for Activation of Phase I and Phase II Detoxification Pathways following an Acute Hypothermic Response in Mice]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/298?rss=1</link>
<description><![CDATA[
<p>Ciguatoxins (CTX) are polyether neurotoxins that target voltage-gated sodium channels and are responsible for ciguatera, the most common fish-borne food poisoning in humans. This study characterizes the global transcriptional response of mouse liver to a symptomatic dose (0.26 ng/g) of the highly potent Pacific ciguatoxin-1 (P-CTX-1). At 1 h post-exposure 2.4% of features on a 44K whole genome array were differentially expressed (<I>p</I> &le; 0.0001), increasing to 5.2% at 4 h and decreasing to 1.4% by 24 h post-CTX exposure. Data were filtered (|fold change| &ge; 1.5 and <I>p</I> &le; 0.0001 in at least one time point) and a trend set of 1550 genes were used for further analysis. Early gene expression was likely influenced prominently by an acute 4&deg;C decline in core body temperature by 1 h, which resolved by 8 h following exposure. An initial downregulation of 32 different solute carriers, many involved in sodium transport, was observed. Differential gene expression in pathways involving eicosanoid biosynthesis and cholesterol homeostasis was also noted. Cytochrome P450s (Cyps) were of particular interest due to their role in xenobiotic metabolism. Twenty-seven genes, mostly members of Cyp2 and Cyp4 families, showed significant changes in expression. Many Cyps underwent an initial downregulation at 1 h but were quickly and strongly upregulated at 4 and 24 h post-exposure. In addition to Cyps, increases in several glutathione <I>S</I>-transferases were observed, an indication that both phase I and phase II metabolic reactions are involved in the hepatic response to CTX in mice.</p>
]]></description>
<dc:creator><![CDATA[Morey, J. S., Ryan, J. C., Bottein Dechraoui, M.-Y., Rezvani, A. H., Levin, E. D., Gordon, C. J., Ramsdell, J. S., Van Dolah, F. M.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn055</dc:identifier>
<dc:title><![CDATA[Liver Genomic Responses to Ciguatoxin: Evidence for Activation of Phase I and Phase II Detoxification Pathways following an Acute Hypothermic Response in Mice]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>310</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>298</prism:startingPage>
<prism:section>ENVIRONMENTAL TOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/311?rss=1">
<title><![CDATA[Khat (Catha edulis) Induces Reactive Oxygen Species and Apoptosis in Normal Human Oral Keratinocytes and Fibroblasts]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/311?rss=1</link>
<description><![CDATA[
<p>Khat chewing is widely practiced in Eastern Africa and the Middle East. Khat is genotoxic to cells within the oral mucosa, and several studies have suggested an association between khat use and oral lesions like hyperkeratosis and oral cancer. This study investigated the mechanism of khat-induced cytotoxicity using primary normal human oral keratinocytes (NOK) and fibroblasts (NOF). Khat induced rounding up of cells, plasma membrane blebbing, and condensation of nuclear chromatin within 3&ndash;6 h of exposure. The cells also showed externalization of phosphatidylserine and fragmentation of DNA. Morphological and biochemical features were compatible with cell death by apoptosis. Khat also induced an increase in cytosolic reactive oxygen species (ROS) and a depletion of intracellular glutathione (GSH) within 1 h of exposure. Antioxidants reduced ROS generation, GSH depletion and delayed the onset of cytotoxicity in both cell types. Generally, NOF cells were more sensitive to khat-induced cytotoxicity than NOK cells. These effects were elicited at concentrations of khat expected to occur in the oral cavity during khat chewing. In summary, khat induced apoptotic cell death in primary normal oral keratinocytes and fibroblasts by an early effect on mechanisms that regulate oxidative stress.</p>
]]></description>
<dc:creator><![CDATA[Lukandu, O. M., Costea, D. E., Neppelberg, E., Johannessen, A. C., Vintermyr, O. K.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn044</dc:identifier>
<dc:title><![CDATA[Khat (Catha edulis) Induces Reactive Oxygen Species and Apoptosis in Normal Human Oral Keratinocytes and Fibroblasts]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>324</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>311</prism:startingPage>
<prism:section>IN VITRO TOXICOLOGY AND ALTERNATIVE TESTING</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/325?rss=1">
<title><![CDATA[Heme-oxygenase 1 Gene Expression is a Marker for Hexavalent Chromium-Induced Stress and Toxicity in Human Dermal Fibroblasts]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/325?rss=1</link>
<description><![CDATA[
<p>Several adverse health effects, including irritant and allergic contact dermatitis, have been reported among workers who are occupationally exposed to chromium-containing compounds. Human dermal fibroblasts were used as an <I>in vitro</I> experimental model to study the potential mechanisms underlying hexavalent chromium [Cr(VI)]&ndash;induced dermal toxicity. Exposure of the fibroblasts to 5&micro;M Cr(VI) (LC50 for a 24-h exposure period) followed by microarray analysis of the gene expression profile revealed overexpression of several genes including those involved in cell stress response. The cellular level of glutathione, the major antioxidant molecule present in the cells, was significantly lower in the Cr(VI)-treated cells compared to the corresponding control cells. The Cr(VI)-induced overexpression of heme-oxygenase 1 messenger RNA (HO-1) in the fibroblasts was significantly blocked by actinomycin D and by inhibitors of MAP kinase pathways. The Cr(VI)-induced cytotoxicity and the overexpression of the HO-1 gene were dependent on the glutathione level of the fibroblasts. Buthionine sulfoximine-mediated GSH depletion resulted in enhanced Cr(VI) cytotoxicity and further overexpression of the HO-1 gene. On the other hand, elevated cellular levels of glutathione resulting from pretreating the cells with GSH significantly protected the cells against the Cr(VI)-induced cytotoxicity and blocked the HO-1 gene's overexpression. Pretreating the fibroblasts with N-acetyl cysteine also significantly reduced the Cr(VI)-induced cytotoxicity and overexpression of the HO-1 gene. In conclusion, depletion of GSH leading to cellular stress is a major mechanism responsible for Cr(VI)-induced cytotoxicity. Furthermore, the expression level of HO-1 gene is a marker for Cr(VI)-induced cell stress leading to cytotoxicity.</p>
]]></description>
<dc:creator><![CDATA[Joseph, P., He, Q., Umbright, C.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn048</dc:identifier>
<dc:title><![CDATA[Heme-oxygenase 1 Gene Expression is a Marker for Hexavalent Chromium-Induced Stress and Toxicity in Human Dermal Fibroblasts]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>334</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>325</prism:startingPage>
<prism:section>IN VITRO TOXICOLOGY AND ALTERNATIVE TESTING</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/335?rss=1">
<title><![CDATA[In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/335?rss=1</link>
<description><![CDATA[
<p>Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity. Nefazodone was withdrawn from the U.S. market in 2004 due to hepatotoxicity. Accordingly, we evaluated nefazodone, another triazolopyridine trazodone, plus the azaspirodecanedione buspirone, for cytotoxicity and effects on mitochondrial function. In accord with its clinical disposition, nefazodone was the most toxic compound of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity. Nefazodone profoundly inhibited mitochondrial respiration in isolated rat liver mitochondria and in intact HepG2 cells where this was accompanied by simultaneous acceleration of glycolysis. Using immunocaptured oxidative phosphorylation (OXPHOS) complexes, we identified Complex 1, and to a lesser amount Complex IV, as the targets of nefazodone toxicity. No inhibition was found for trazodone, and buspirone showed 3.4-fold less inhibition of OXPHOS Complex 1 than nefazodone. In human hepatocytes that express cytochrome P450, isoform 3A4, after 24 h exposure, nefazodone and trazodone collapsed mitochondrial membrane potential, and imposed oxidative stress, as detected via glutathione depletion, leading to cell death. Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, especially in patients cotreated with other drugs with mitochondrial liabilities.</p>
]]></description>
<dc:creator><![CDATA[Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., Will, Y.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn056</dc:identifier>
<dc:title><![CDATA[In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>345</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>335</prism:startingPage>
<prism:section>IN VITRO TOXICOLOGY AND ALTERNATIVE TESTING</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/346?rss=1">
<title><![CDATA[Na+/H+ Exchanger-1 Inhibitors Reduce Neuronal Excitability and Alter Na+ Channel Inactivation Properties in Rat Primary Sensory Neurons]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/346?rss=1</link>
<description><![CDATA[
<p>Inhibitors of the Na<sup>+</sup>/H<sup>+</sup> exchanger isoform 1 (NHE-1) have been associated with peripheral neuropathy in rats and dogs. Recent studies suggest that NHE-1 plays an important role in mediating neuronal excitability. To investigate potential NHE-1-mediated mechanisms contributing to neuronal toxicity, we studied the effects of NHE-1 inhibitors on nerve and dorsal root ganglion (DRG) neurons isolated from the adult rat. Compound action potentials (CAPs) were recorded from electrically stimulated sections of isolated sciatic nerve/DRG/root preparations. Whole-cell patch-clamp technique was used to record fast and slow voltage-dependent Na<sup>+</sup> currents from dissociated DRG neurons (29&ndash;41 &micro;m). Exposures to 1 and 10&micro;M of a selective NHE-1 inhibitor reduced the amplitude of the CAP recorded from the dorsal root by 33% and 58%, respectively (<I>p</I> &lt; 0.05). The compound had no effect on CAPs recorded from the ventral root. Perfusion of dissociated DRG neurons with NHE-1 inhibitors at 10 and 100&micro;M shifted voltage-dependent inactivation curves of fast Na<sup>+</sup> current by as much as 11 mV (<I>p</I> &lt; 0.001) in the hyperpolarizing direction. No shift was observed in slow Na<sup>+</sup> currents. No statistically significant drug effects were observed on voltage-dependent activation or recovery from inactivation of either fast or slow Na<sup>+</sup> currents. These results suggest that NHE-1 inhibitors may reduce peripheral neuronal excitability by shifting fast Na<sup>+</sup> channels into the inactivated state under physiological conditions. Such effects may underlie peripheral neuropathies reported in rats and dogs with NHE-1 inhibitors.</p>
]]></description>
<dc:creator><![CDATA[Liu, C.-N., Somps, C. J.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn045</dc:identifier>
<dc:title><![CDATA[Na+/H+ Exchanger-1 Inhibitors Reduce Neuronal Excitability and Alter Na+ Channel Inactivation Properties in Rat Primary Sensory Neurons]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>353</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>346</prism:startingPage>
<prism:section>NEUROTOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/354?rss=1">
<title><![CDATA[Neurotoxicological Evaluation of Long-Term Lanthanum Chloride Exposure in Rats]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/354?rss=1</link>
<description><![CDATA[
<p>With their widespread application in industry, agriculture, medicine, and daily life, rare earth elements (REEs) are widely used in various fields and eventually accumulated in human body. Therefore, understanding the effects of REEs on health has become more and more important. In this work, the neurotoxicity of lanthanum (La) was evaluated. Wistar rats were exposed to lanthanum chloride through oral administration at 0, 0.1, 2, and 40 mg/kg doses from gestation day 0 through 6 months of age. Experiments were carried out to reveal the effects of La exposure on brain functions from four aspects including behavioral performance, [Ca<sup>2+</sup>]<I><SUB>i</SUB></I> level and the activity of Ca<sup>2+</sup>-ATPase (adenosine triphosphatase) in hippocampal cells, oxidative stress, and Nissl staining. Adverse effects were observed in 2 and 40 mg/kg dose groups and increased with dose. Morris water maze test showed that La exposure at 2 and 40 mg/kg could significantly impair the behavioral performance. (The preference for the target quadrant decreased by 16.6% and 19.4% versus control, respectively.) The neurotoxicological consequences demonstrated that the alteration in homeostasis of [Ca<sup>2+</sup>]<I><SUB>i</SUB></I>/Ca<sup>2+</sup>-ATPase (the ratio of [Ca<sup>2+</sup>]<I><SUB>i</SUB></I> vs. Ca<sup>2+</sup>-ATPase activity increased by 44% in rats of 40 mg/kg group), the inhibition to activities of antioxidant enzymes, and the subsequent cell damage (18% and 23% cell loss in CA3 subregion of rats in 2 and 40 mg/kg group, respectively) might be involved in the neurological adverse effects of REEs exposure.</p>
]]></description>
<dc:creator><![CDATA[He, X., Zhang, Z., Zhang, H., Zhao, Y., Chai, Z.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn046</dc:identifier>
<dc:title><![CDATA[Neurotoxicological Evaluation of Long-Term Lanthanum Chloride Exposure in Rats]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>361</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>354</prism:startingPage>
<prism:section>NEUROTOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/362?rss=1">
<title><![CDATA[Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/362?rss=1</link>
<description><![CDATA[
<p>In Canada, nicotine replacement therapy is recommended as a safe smoking cessation aid for pregnant women. However, we have shown in an animal model that fetal and neonatal nicotine exposure causes increased beta-cell apoptosis and loss of beta-cell mass, which leads to the development of postnatal dysglycemia and obesity. The goal of this study was to determine whether the observed beta-cell apoptosis is mediated via the mitochondrial and/or death receptor pathway. Female Wistar rats were given saline (control) or nicotine bitartrate (1 mg/kg/day) via sc injection for 2 weeks prior to mating until weaning (postnatal day 21). At weaning, pancreas tissue was collected for Western blotting, electron microscopy (EM), and immunohistochemistry. Key markers of each apoptotic pathway were examined in whole pancreas homogenates and mitochondrial/cytosolic pancreas fractions. In the death receptor pathway, Fas and soluble Fas ligand (FasL) protein were significantly increased in the nicotine-exposed offspring compared to control animals; there was no difference in the ratio of inactive/active caspase-8 or membrane-bound FasL expression. In the mitochondrial pathway, there was a significant increase in the ratio of Bcl2/Bax, Bax translocation to the mitochondria, cytochrome <I>c</I> release to the cytosol, and the ratio of active/inactive caspase-3 in nicotine-exposed offspring relative to control animals. Furthermore, increased mitochondrial swelling was observed by EM in the pancreatic beta cells of nicotine-exposed offspring. Taken together, these data suggest that beta-cell apoptosis following developmental nicotine exposure is mediated via the mitochondria.</p>
]]></description>
<dc:creator><![CDATA[Bruin, J. E., Gerstein, H. C., Morrison, K. M., Holloway, A. C.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn012</dc:identifier>
<dc:title><![CDATA[Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>370</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>362</prism:startingPage>
<prism:section>REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/371?rss=1">
<title><![CDATA[Evaluation of Putative Biomarkers of Nephrotoxicity after Exposure to Ochratoxin A In Vivo and In Vitro]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/371?rss=1</link>
<description><![CDATA[
<p>The kidney is one of the main targets of xenobiotic-induced toxicity, but early detection of renal damage is difficult. Recently, several novel biomarkers of nephrotoxicity have been identified by transcription profiling, including kidney injury molecule-1 (Kim-1), lipocalin-2, tissue inhibitor of metalloproteinases-1 (Timp-1), clusterin, osteopontin (OPN), and vimentin, and suggested as sensitive endpoints for acute kidney injury <I>in vivo</I>. However, it is not known if these cellular marker molecules may also be useful to predict chronic nephrotoxicity or to detect nephrotoxic effects <I>in vitro</I>. In this study, a panel of new biomarkers of renal toxicity was assessed via quantitative real-time PCR, immunohistochemistry, and immunoblotting in rats treated with the nephrotoxin ochratoxin A (OTA) for up to 90 days and in rat proximal tubule cells (NRK-52E) treated with OTA <I>in vitro</I>. Repeated administration of OTA to male F344/N rats for 14, 28, or 90 days resulted in a dose- and time-dependent increase in the expression of Kim-1, Timp-1, lipocalin-2, OPN, clusterin, and vimentin. Changes in gene expression were found to correlate with the progressive histopathological alterations and preceded effects on traditional clinical parameters indicative of impaired kidney function. Induction of Kim-1 messenger RNA expression was the earliest and most prominent response observed, supporting the use of this marker as sensitive indicator of chronic kidney injury. In contrast, no significant increase in the expression of putative marker genes and proteins were evident in NRK-52E cells after exposure to OTA for up to 48 h, suggesting that they may not be suitable endpoints for sensitive detection of nephrotoxic effects <I>in vitro</I>.</p>
]]></description>
<dc:creator><![CDATA[Rached, E., Hoffmann, D., Blumbach, K., Weber, K., Dekant, W., Mally, A.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn040</dc:identifier>
<dc:title><![CDATA[Evaluation of Putative Biomarkers of Nephrotoxicity after Exposure to Ochratoxin A In Vivo and In Vitro]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>381</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>371</prism:startingPage>
<prism:section>SAFETY EVALUATION</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/382?rss=1">
<title><![CDATA[Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/382?rss=1</link>
<description><![CDATA[
<p>Fatty acid binding protein 3 (Fabp3) has been used as a serological biomarker of cardiac injury, but its utility as a preclinical biomarker of injury to skeletal muscle is not well described. Fabp3 concentrations were determined for tissues from Sprague&ndash;Dawley rats and found to occur at highest concentrations in cardiac muscle and in skeletal muscles containing an abundance of type I fibers, such as the soleus muscle. Soleus is also a primary site of skeletal muscle (SKM) injury caused by lipid-lowering peroxisome proliferator&ndash;activated receptor alpha (PPAR-) agonists. In rats administered repeat doses of a PPAR- agonist, the kinetics and amplitude of plasma concentrations of Fabp3 were consistent with plasma compound concentrations and histopathology findings of swollen, hyalinized, and fragmented muscle fibers with macrophage infiltration. Immunohistochemical detection of Fabp3 revealed focal depletion of Fabp3 protein from injured SKM fibers which is consistent with increased serum Fabp3 concentrations in treated rats. We then assessed the predictivity of serological Fabp3 for SKM necrosis in short duration toxicology studies. Rats were treated with various doses of 27 different compounds, and the predictivity of serological biomarkers was assessed relative to histology in individual rats and in treatment groups. Under these study conditions, Fabp3 was the most useful individual biomarker based on concordance, sensitivity, positive and negative predictive values, and false negative rate. In addition, the combination of Fabp3 and aspartate aminotransferase (AST) had greater diagnostic value than the conventional combination of creatine kinase-MM isoenzyme (CK) and AST.</p>
]]></description>
<dc:creator><![CDATA[Pritt, M. L., Hall, D. G., Recknor, J., Credille, K. M., Brown, D. D., Yumibe, N. P., Schultze, A. E., Watson, D. E.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn042</dc:identifier>
<dc:title><![CDATA[Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>396</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>382</prism:startingPage>
<prism:section>SAFETY EVALUATION</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/397?rss=1">
<title><![CDATA[Renal Anemia Induced by Chronic Ingestion of Depleted Uranium in Rats]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/397?rss=1</link>
<description><![CDATA[
<p>Kidney disease is a frequent consequence of heavy metal exposure and renal anemia occurs secondarily to the progression of kidney deterioration into chronic disease. In contrast, little is known about effects on kidney of chronic exposure to low levels of depleted uranium (DU). Study was performed with rats exposed to DU at 40 mg/l by chronic ingestion during 9 months. In the present work, a ~20% reduction in red blood cell (RBC) count was observed after DU exposure. Hence, three hypotheses were tested to determinate origin of RBC loss: (1) reduced erythropoiesis, (2) increased RBC degradation, and/or (3) kidney dysfunction. Erythropoiesis was not reduced after exposure to DU as revealed by erythroid progenitors, blood Flt3 ligand and erythropoietin (EPO) blood and kidney levels. Concerning messenger RNA (mRNA) and protein levels of spleen iron recycling markers from RBC degradation (DMT1 [divalent metal transporter 1], iron regulated protein 1, HO1, HO2 [heme oxygenase 1 and 2], cluster of differentiation 36), increase in HO2 and DMT1 mRNA level was induced after chronic exposure to DU. Kidneys of DU-contaminated rats had more frequently high grade tubulo-interstitial and glomerular lesions, accumulated iron more frequently and presented more apoptotic cells. In addition, chronic exposure to DU induced increased gene expression of ceruloplasmin (<FONT FACE="arial,helvetica">x</FONT>12), of DMT1 (<FONT FACE="arial,helvetica">x</FONT>2.5), and decreased mRNA levels of erythropoietin receptor (<FONT FACE="arial,helvetica">x</FONT>0.2). Increased mRNA level of DMT1 was associated to decreased protein level (<FONT FACE="arial,helvetica">x</FONT>0.25). To conclude, a chronic ingestion of DU leads mainly to kidney deterioration that is probably responsible for RBC count decrease in rats. Spleen erythropoiesis and molecules involved in erythrocyte degradation were also modified by chronic DU exposure.</p>
]]></description>
<dc:creator><![CDATA[Berradi, H., Bertho, J.-M., Dudoignon, N., Mazur, A., Grandcolas, L., Baudelin, C., Grison, S., Voisin, P., Gourmelon, P., Dublineau, I.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn052</dc:identifier>
<dc:title><![CDATA[Renal Anemia Induced by Chronic Ingestion of Depleted Uranium in Rats]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>408</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>397</prism:startingPage>
<prism:section>SAFETY EVALUTION</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/409?rss=1">
<title><![CDATA[Use of the Pup as the Statistical Unit in Developmental Neurotoxicity Studies: Overlooked Model or Poor Research Design?]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/409?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Hardy, M., Stedeford, T.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn036</dc:identifier>
<dc:title><![CDATA[Use of the Pup as the Statistical Unit in Developmental Neurotoxicity Studies: Overlooked Model or Poor Research Design?]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>410</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>409</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/411?rss=1">
<title><![CDATA[Response to: Use of the Pup as the Statistical Unit in Developmental Neurotoxicity Studies: Overlooked Model or Poor Research Design?]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/411?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Eriksson, P.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn037</dc:identifier>
<dc:title><![CDATA[Response to: Use of the Pup as the Statistical Unit in Developmental Neurotoxicity Studies: Overlooked Model or Poor Research Design?]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>413</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>411</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/414?rss=1">
<title><![CDATA[Modeling Neurodevelopment Outcomes and Ethylmercury Exposure from Thimerosal-Containing Vaccines]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/414?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Dorea, J. G., Marques, R. C.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn049</dc:identifier>
<dc:title><![CDATA[Modeling Neurodevelopment Outcomes and Ethylmercury Exposure from Thimerosal-Containing Vaccines]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>415</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>414</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/416?rss=1">
<title><![CDATA[Modeling Neonatal Thimerosal Exposure in Mice]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/416?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Berman, R. F., Pessah, I. N., Mouton, P. R., Mav, D., Harry, G. J.]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn051</dc:identifier>
<dc:title><![CDATA[Modeling Neonatal Thimerosal Exposure in Mice]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>416</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>416</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://toxsci.oxfordjournals.org/cgi/content/short/103/2/417?rss=1">
<title><![CDATA[ERRATUM]]></title>
<link>http://toxsci.oxfordjournals.org/cgi/content/short/103/2/417?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-05-07</dc:date>
<dc:identifier>info:doi/10.1093/toxsci/kfn069</dc:identifier>
<dc:title><![CDATA[ERRATUM]]></dc:title>
<dc:publisher>Society of Toxicology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>103</prism:volume>
<prism:endingPage>417</prism:endingPage>
<prism:publicationDate>2008-06-01</prism:publicationDate>
<prism:startingPage>417</prism:startingPage>
<prism:section>ERRATUM</prism:section>
</item>

</rdf:RDF>